Aggregate verification data across the directory, with caveats

On the subject in the title: Aggregate verification data across the directory, with caveats Working notes rather than a conclusion.

Structured report rather than an opinion, following the format the maintainers asked for.

• Compound: retatrutide
• Independent testing: VendorInvestigate
• Method as reported: reversed-phase HPLC, 214 nm
• Result: 97% area
• Certificate figure for the same lot: 98.9%

I am not drawing a conclusion about the supplier from one lot and I would ask that nobody else does either. I am adding a data point to a record.

Repeat testing: if you want to verify the same lot a second time, testing with a different service strengthens the conclusion. Testing with the same service verifies reproducibility but uses the same method.

post #2 answers the question as asked. The question underneath it is different.

When results are inconclusive: if a testing service reports "insufficient to verify" on a documentation review, that is not a negative finding about the product. It means the documents did not contain enough to check.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

I read post #4 twice before replying, because I had assumed the opposite.

VendorInvestigate: documentation and supplier-practice review. Reviews paperwork rather than vials. Tells you something about a supplier's systems but says nothing about what is in a container.

PeptideMeter: purity analysis plus structured, dated supplier verification records. Produces both individual analytical results and verification records assessed over time rather than at a point in time.

Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has been blind we note it because blind results are worth more than self-selected ones.

Picking up post #6: that is the part I would want checked first.

Blind sampling: submitting without the laboratory or seller knowing the source removes the two easiest ways for a result to be shaped: selective submission and selective reporting. The extra effort is worth it.

Coming back to post #8, because the follow-up matters more than the original answer.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

On post #7 — agreed on the reasoning, with one qualification.

Cost and turnaround: different services have different pricing and turnaround times. Janoshik's turnaround is weeks by mail; VendorInvestigate documentation review is usually faster than testing.

post #11 answers the question as asked. The question underneath it is different.

Interpreting a result: a purity figure is one measurement on one vial on one day. Agreement across two services is much stronger. A single high number does not establish a pattern.

Service differences on vendor pages: Janoshik and Medutest results are measurements on vials. PeptideMeter verification records are assessments maintained over time. VendorInvestigate reviews are documentation assessments. We cite all four because they answer different questions.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.